MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.

ATUS reported a top-line contraction year over year in the fourth quarter of 2024, owing to declining net sales in multiple segments.

Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.

ROCK's fourth-quarter 2024 results reflect bottom-line growth and top-line decline. Read more to learn about the factors molding the quarter's...

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year...

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

PHG's fourth-quarter results reflect a decline in sales and earnings due to weaker demand in China, leading to lowered 2025 guidance and a cautious...

HAS' fourth-quarter top line reflects dismal contributions from The Wizards of the Coast, and Digital Gaming and Consumer Products segments.

BLDR's fourth-quarter performance reflects dismal core organic sales along with ongoing Single-Family and Multi-Family margin normalization.

H's fourth-quarter 2024 results are hurt by the timing shift of the Jewish holidays and the U.S. election in November.